Hospital-Acquired Pneumonia

Lee E. Morrow, Marin H. Kollef

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Hospital-acquired pneumonia (HAP) is a new infection of the lung parenchyma that develops more than 48 hours after hospital admission. Epidemiologic data suggest that HAP occurs in up to 1% of patients, prolongs hospital stay by 7 to 9 days, and represents the most common hospital-acquired infection leading to death. The morbidity and mortality attributed to HAP are significantly increased if infection is caused by multidrug-resistant pathogens. The subset of HAP occurring more than 48 hours after initiation of mechanical ventilation is termed ventilator-associated pneumonia (VAP). Risk factors for HAP and VAP are diverse and include both patient-specific and treatment-associated elements. Clinical defining criteria for pneumonia require a new or worsening infiltrate on chest radiography in conjunction with typical clinical and laboratory findings. Although microbiologic confirmation is ideal, the optimal diagnostic strategy is hotly debated. Recent trends in the microbial resistance rates for pathogens causing HAP have led to significant changes in the recommendations for empirical therapy, with an increased reliance on broad-spectrum therapy followed by culture-based deescalation. Empirical treatment decisions must also take into consideration local microbiologic data, host-specific risk factors, and the severity of the patient's acute illness. Limited new antibiotic development and high attributable mortality rates highlight the importance of evidence-based HAP prevention strategies.

Original languageEnglish
Title of host publicationNetter's Infectious Disease
PublisherElsevier Inc.
Pages137-145
Number of pages9
ISBN (Electronic)9781437701265
ISBN (Print)9781437701265
DOIs
StatePublished - Sep 9 2011

Fingerprint

Pneumonia
Ventilator-Associated Pneumonia
Mortality
Therapeutics
Cross Infection
Infection
Artificial Respiration
Radiography
Length of Stay
Thorax
Anti-Bacterial Agents
Morbidity
Lung

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Morrow, L. E., & Kollef, M. H. (2011). Hospital-Acquired Pneumonia. In Netter's Infectious Disease (pp. 137-145). Elsevier Inc.. https://doi.org/10.1016/B978-1-4377-0126-5.00027-6

Hospital-Acquired Pneumonia. / Morrow, Lee E.; Kollef, Marin H.

Netter's Infectious Disease. Elsevier Inc., 2011. p. 137-145.

Research output: Chapter in Book/Report/Conference proceedingChapter

Morrow, LE & Kollef, MH 2011, Hospital-Acquired Pneumonia. in Netter's Infectious Disease. Elsevier Inc., pp. 137-145. https://doi.org/10.1016/B978-1-4377-0126-5.00027-6
Morrow LE, Kollef MH. Hospital-Acquired Pneumonia. In Netter's Infectious Disease. Elsevier Inc. 2011. p. 137-145 https://doi.org/10.1016/B978-1-4377-0126-5.00027-6
Morrow, Lee E. ; Kollef, Marin H. / Hospital-Acquired Pneumonia. Netter's Infectious Disease. Elsevier Inc., 2011. pp. 137-145
@inbook{9915c5902bcd4782bc5251a3e57b10b5,
title = "Hospital-Acquired Pneumonia",
abstract = "Hospital-acquired pneumonia (HAP) is a new infection of the lung parenchyma that develops more than 48 hours after hospital admission. Epidemiologic data suggest that HAP occurs in up to 1{\%} of patients, prolongs hospital stay by 7 to 9 days, and represents the most common hospital-acquired infection leading to death. The morbidity and mortality attributed to HAP are significantly increased if infection is caused by multidrug-resistant pathogens. The subset of HAP occurring more than 48 hours after initiation of mechanical ventilation is termed ventilator-associated pneumonia (VAP). Risk factors for HAP and VAP are diverse and include both patient-specific and treatment-associated elements. Clinical defining criteria for pneumonia require a new or worsening infiltrate on chest radiography in conjunction with typical clinical and laboratory findings. Although microbiologic confirmation is ideal, the optimal diagnostic strategy is hotly debated. Recent trends in the microbial resistance rates for pathogens causing HAP have led to significant changes in the recommendations for empirical therapy, with an increased reliance on broad-spectrum therapy followed by culture-based deescalation. Empirical treatment decisions must also take into consideration local microbiologic data, host-specific risk factors, and the severity of the patient's acute illness. Limited new antibiotic development and high attributable mortality rates highlight the importance of evidence-based HAP prevention strategies.",
author = "Morrow, {Lee E.} and Kollef, {Marin H.}",
year = "2011",
month = "9",
day = "9",
doi = "10.1016/B978-1-4377-0126-5.00027-6",
language = "English",
isbn = "9781437701265",
pages = "137--145",
booktitle = "Netter's Infectious Disease",
publisher = "Elsevier Inc.",
address = "United States",

}

TY - CHAP

T1 - Hospital-Acquired Pneumonia

AU - Morrow, Lee E.

AU - Kollef, Marin H.

PY - 2011/9/9

Y1 - 2011/9/9

N2 - Hospital-acquired pneumonia (HAP) is a new infection of the lung parenchyma that develops more than 48 hours after hospital admission. Epidemiologic data suggest that HAP occurs in up to 1% of patients, prolongs hospital stay by 7 to 9 days, and represents the most common hospital-acquired infection leading to death. The morbidity and mortality attributed to HAP are significantly increased if infection is caused by multidrug-resistant pathogens. The subset of HAP occurring more than 48 hours after initiation of mechanical ventilation is termed ventilator-associated pneumonia (VAP). Risk factors for HAP and VAP are diverse and include both patient-specific and treatment-associated elements. Clinical defining criteria for pneumonia require a new or worsening infiltrate on chest radiography in conjunction with typical clinical and laboratory findings. Although microbiologic confirmation is ideal, the optimal diagnostic strategy is hotly debated. Recent trends in the microbial resistance rates for pathogens causing HAP have led to significant changes in the recommendations for empirical therapy, with an increased reliance on broad-spectrum therapy followed by culture-based deescalation. Empirical treatment decisions must also take into consideration local microbiologic data, host-specific risk factors, and the severity of the patient's acute illness. Limited new antibiotic development and high attributable mortality rates highlight the importance of evidence-based HAP prevention strategies.

AB - Hospital-acquired pneumonia (HAP) is a new infection of the lung parenchyma that develops more than 48 hours after hospital admission. Epidemiologic data suggest that HAP occurs in up to 1% of patients, prolongs hospital stay by 7 to 9 days, and represents the most common hospital-acquired infection leading to death. The morbidity and mortality attributed to HAP are significantly increased if infection is caused by multidrug-resistant pathogens. The subset of HAP occurring more than 48 hours after initiation of mechanical ventilation is termed ventilator-associated pneumonia (VAP). Risk factors for HAP and VAP are diverse and include both patient-specific and treatment-associated elements. Clinical defining criteria for pneumonia require a new or worsening infiltrate on chest radiography in conjunction with typical clinical and laboratory findings. Although microbiologic confirmation is ideal, the optimal diagnostic strategy is hotly debated. Recent trends in the microbial resistance rates for pathogens causing HAP have led to significant changes in the recommendations for empirical therapy, with an increased reliance on broad-spectrum therapy followed by culture-based deescalation. Empirical treatment decisions must also take into consideration local microbiologic data, host-specific risk factors, and the severity of the patient's acute illness. Limited new antibiotic development and high attributable mortality rates highlight the importance of evidence-based HAP prevention strategies.

UR - http://www.scopus.com/inward/record.url?scp=84943235876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943235876&partnerID=8YFLogxK

U2 - 10.1016/B978-1-4377-0126-5.00027-6

DO - 10.1016/B978-1-4377-0126-5.00027-6

M3 - Chapter

AN - SCOPUS:84943235876

SN - 9781437701265

SP - 137

EP - 145

BT - Netter's Infectious Disease

PB - Elsevier Inc.

ER -